Pfizer

Pfizer's shares have tumbled about 38% over five years as COVID-19 revenues collapsed and key drugs face patent cliffs, while acquisitions such as Seagen and Metsera pushed net debt above $53 billion. Despite these challenges, Pfizer generated nearly $11 billion in free cash flow over the last twelve months and saw 21% revenue growth from Seagen's cancer portfolio. The stock's 6% dividend yield reflects the discount, and the payout could remain sustainable if Pfizer reduces debt and grows through acquisitions and its pipeline. » More on finance.yahoo.com

Pfizer reported 1% operational revenue growth in Q2 2026 to $15.0 billion, with revenue excluding Comirnaty and Paxlovid up 5% and launched/acquired products generating $3.2 billion (up 18% operationally). Padcev and the Vyndaqel family posted strong gains, while management raised the midpoint of full-year guidance and expects about $5.7 billion in net savings by end-2026. The company remains exposed to looming patent expirations on drugs such as Eliquis, Ibrance and Xtandi, with an estimated $1.1 billion unfavorable revenue impact in 2026 from generics and biosimilars, leaving uncertainty whether new products can fully offset lost franchise revenue. » More on finance.yahoo.com

Pfizer yields 6.4% and is maintaining its dividend while facing major patent expirations for Ibrance and Xtandi in 2027 and Eliquis in 2028, which has pressured investor sentiment. The company dropped an internal GLP-1 candidate in 2025 but acquired a stronger program and continues to advance oncology and migraine assets. Pfizer forecasts new drugs, internal or acquired, will drive high-single-digit revenue growth after 2028, making a revenue recovery by 2030 likely if it weathers the upcoming expirations. » More on finance.yahoo.com